Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.
about
Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunityImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.Positive choices: outcomes of a brief risk reduction intervention for newly HIV-diagnosed men who have sex with men.Can early therapy reduce inflammation?Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance.Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected PersonsSilymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cellsThe Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon.Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery.Efferocytosis of Pathogen-Infected Cells.Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected IndividualsHIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction
P2860
Q26773267-5774E5D2-4284-4635-AA26-3EE7EAB44E29Q27687272-E75CE492-D8A8-43C3-9749-68D0DCBADD4CQ33749579-26194964-4B65-45B9-93D3-F233D93D1D77Q34021910-8A98078D-61C3-4424-83A4-15BCA16FF092Q34159822-5C164AAB-2610-447C-BA90-28CC4BB32F7DQ35018886-F56597DE-CA98-4FF5-899E-8858BFA047C3Q35813218-B60C2964-2178-44F7-8E2B-BD7C3450C1EEQ36241275-FB0C0C2F-F625-40D7-A058-ED8169C1BBA3Q36269639-BDEE8C6F-0241-4978-B66B-C3D18448D973Q37324462-CF38B951-B21E-41E2-B428-12449CDB4A28Q40088680-CF1465EB-F954-4DEF-B806-84DFE66C766FQ41057213-4892F440-5FAA-437B-A963-9D6A61B4A682Q47171468-46C82449-AFF9-402F-99F3-814185C1F580Q58694946-305E4BF4-D0EE-43C1-BFFE-C93202D52E68Q58701373-12C72613-B358-4AED-88BA-08CDA6809ACB
P2860
Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Understanding and controlling ...... nation antiretroviral therapy.
@en
type
label
Understanding and controlling ...... nation antiretroviral therapy.
@en
prefLabel
Understanding and controlling ...... nation antiretroviral therapy.
@en
P2860
P1476
Understanding and controlling ...... nation antiretroviral therapy.
@en
P2093
Luis Barcena
Randall Tressler
P2860
P2888
P356
10.1007/S11904-012-0147-3
P577
2013-03-01T00:00:00Z